PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer

Yota Yasumizu, Hiroshi Hongo, Takeo Kosaka, Shuji Mikami, Koshiro Nishimoto, Eiji Kikuchi, Mototsugu Oya

Research output: Contribution to journalArticle

Abstract

The aim of this study was to explore the efficacy of mTOR inhibitor for castrationresistant prostate cancer (CRPC) under hypoxia. Although under normoxia C4-2AT6, it is a CRPC cell line, expressed elevated pAkt, pS6 and Pyruvate kinase M2 (PKM2) accompanied by elevated HIF-1a expression, 5% hypoxic condition further induced expression of these proteins. These results indicate hypoxic environment elevated PI3K/ Akt/mTOR pathway in aggressive prostate cancer. However, C4-2AT6 cells treated with mTOR inhibitor under hypoxia less decreased compared to cells treated with the same dose drugs under normoxia. Western blot analysis showed mTOR inhibitor: RAD001 not only inhibited pS6, but also increased the expression of PKM2 in a dose and time dependent manner. Pyruvate kinase acts on glycolysis. PKM2, which is frequently express in tumor cells, is one isoform of pyruvate kinase. PKM2 is reported to act as a transcription factor. In the present study overexpression of PKM2 in C4-2AT6 induced resistance to RAD001 under normoxia. To evaluate the therapeutic effect of targeting PKM2, we inhibited PKM2 in C4-2AT6 under hypoxia using si-PKM2. The number of C4-2AT6 under chronic hypoxia exposed to siPKM2 significantly decreased compared to intact C4-2AT6 under chronic hypoxia. Furthermore, si-PKM2 improved resistance to mTOR inhibitor in C4-2AT6. When examined using clinical samples, high PKM2 expression was correlated with a high Gleason score and poor PSA free survival. These results suggested that up-regulation of PKM2 is one possibility of resistance to mTOR inhibitor in CRPC. And it is possible that PKM2 is a useful therapeutic target of CRPC.

Original languageEnglish
Pages (from-to)27698-27707
Number of pages10
JournalOncotarget
Volume9
Issue number45
DOIs
Publication statusPublished - 2018 Jun 12

Fingerprint

Pyruvate Kinase
Castration
Prostatic Neoplasms
Neoplasm Grading
Therapeutic Uses
Glycolysis
Phosphatidylinositol 3-Kinases

Keywords

  • C4-2AT6
  • CRPC
  • Hypoxias
  • PI3K-Akt-mTOR signaling pathways
  • PKM2

ASJC Scopus subject areas

  • Oncology

Cite this

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer. / Yasumizu, Yota; Hongo, Hiroshi; Kosaka, Takeo; Mikami, Shuji; Nishimoto, Koshiro; Kikuchi, Eiji; Oya, Mototsugu.

In: Oncotarget, Vol. 9, No. 45, 12.06.2018, p. 27698-27707.

Research output: Contribution to journalArticle

Yasumizu, Yota ; Hongo, Hiroshi ; Kosaka, Takeo ; Mikami, Shuji ; Nishimoto, Koshiro ; Kikuchi, Eiji ; Oya, Mototsugu. / PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer. In: Oncotarget. 2018 ; Vol. 9, No. 45. pp. 27698-27707.
@article{0b936eb13ed842c4a99782f041a20998,
title = "PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer",
abstract = "The aim of this study was to explore the efficacy of mTOR inhibitor for castrationresistant prostate cancer (CRPC) under hypoxia. Although under normoxia C4-2AT6, it is a CRPC cell line, expressed elevated pAkt, pS6 and Pyruvate kinase M2 (PKM2) accompanied by elevated HIF-1a expression, 5{\%} hypoxic condition further induced expression of these proteins. These results indicate hypoxic environment elevated PI3K/ Akt/mTOR pathway in aggressive prostate cancer. However, C4-2AT6 cells treated with mTOR inhibitor under hypoxia less decreased compared to cells treated with the same dose drugs under normoxia. Western blot analysis showed mTOR inhibitor: RAD001 not only inhibited pS6, but also increased the expression of PKM2 in a dose and time dependent manner. Pyruvate kinase acts on glycolysis. PKM2, which is frequently express in tumor cells, is one isoform of pyruvate kinase. PKM2 is reported to act as a transcription factor. In the present study overexpression of PKM2 in C4-2AT6 induced resistance to RAD001 under normoxia. To evaluate the therapeutic effect of targeting PKM2, we inhibited PKM2 in C4-2AT6 under hypoxia using si-PKM2. The number of C4-2AT6 under chronic hypoxia exposed to siPKM2 significantly decreased compared to intact C4-2AT6 under chronic hypoxia. Furthermore, si-PKM2 improved resistance to mTOR inhibitor in C4-2AT6. When examined using clinical samples, high PKM2 expression was correlated with a high Gleason score and poor PSA free survival. These results suggested that up-regulation of PKM2 is one possibility of resistance to mTOR inhibitor in CRPC. And it is possible that PKM2 is a useful therapeutic target of CRPC.",
keywords = "C4-2AT6, CRPC, Hypoxias, PI3K-Akt-mTOR signaling pathways, PKM2",
author = "Yota Yasumizu and Hiroshi Hongo and Takeo Kosaka and Shuji Mikami and Koshiro Nishimoto and Eiji Kikuchi and Mototsugu Oya",
year = "2018",
month = "6",
day = "12",
doi = "10.18632/oncotarget.25498",
language = "English",
volume = "9",
pages = "27698--27707",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "45",

}

TY - JOUR

T1 - PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer

AU - Yasumizu, Yota

AU - Hongo, Hiroshi

AU - Kosaka, Takeo

AU - Mikami, Shuji

AU - Nishimoto, Koshiro

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

PY - 2018/6/12

Y1 - 2018/6/12

N2 - The aim of this study was to explore the efficacy of mTOR inhibitor for castrationresistant prostate cancer (CRPC) under hypoxia. Although under normoxia C4-2AT6, it is a CRPC cell line, expressed elevated pAkt, pS6 and Pyruvate kinase M2 (PKM2) accompanied by elevated HIF-1a expression, 5% hypoxic condition further induced expression of these proteins. These results indicate hypoxic environment elevated PI3K/ Akt/mTOR pathway in aggressive prostate cancer. However, C4-2AT6 cells treated with mTOR inhibitor under hypoxia less decreased compared to cells treated with the same dose drugs under normoxia. Western blot analysis showed mTOR inhibitor: RAD001 not only inhibited pS6, but also increased the expression of PKM2 in a dose and time dependent manner. Pyruvate kinase acts on glycolysis. PKM2, which is frequently express in tumor cells, is one isoform of pyruvate kinase. PKM2 is reported to act as a transcription factor. In the present study overexpression of PKM2 in C4-2AT6 induced resistance to RAD001 under normoxia. To evaluate the therapeutic effect of targeting PKM2, we inhibited PKM2 in C4-2AT6 under hypoxia using si-PKM2. The number of C4-2AT6 under chronic hypoxia exposed to siPKM2 significantly decreased compared to intact C4-2AT6 under chronic hypoxia. Furthermore, si-PKM2 improved resistance to mTOR inhibitor in C4-2AT6. When examined using clinical samples, high PKM2 expression was correlated with a high Gleason score and poor PSA free survival. These results suggested that up-regulation of PKM2 is one possibility of resistance to mTOR inhibitor in CRPC. And it is possible that PKM2 is a useful therapeutic target of CRPC.

AB - The aim of this study was to explore the efficacy of mTOR inhibitor for castrationresistant prostate cancer (CRPC) under hypoxia. Although under normoxia C4-2AT6, it is a CRPC cell line, expressed elevated pAkt, pS6 and Pyruvate kinase M2 (PKM2) accompanied by elevated HIF-1a expression, 5% hypoxic condition further induced expression of these proteins. These results indicate hypoxic environment elevated PI3K/ Akt/mTOR pathway in aggressive prostate cancer. However, C4-2AT6 cells treated with mTOR inhibitor under hypoxia less decreased compared to cells treated with the same dose drugs under normoxia. Western blot analysis showed mTOR inhibitor: RAD001 not only inhibited pS6, but also increased the expression of PKM2 in a dose and time dependent manner. Pyruvate kinase acts on glycolysis. PKM2, which is frequently express in tumor cells, is one isoform of pyruvate kinase. PKM2 is reported to act as a transcription factor. In the present study overexpression of PKM2 in C4-2AT6 induced resistance to RAD001 under normoxia. To evaluate the therapeutic effect of targeting PKM2, we inhibited PKM2 in C4-2AT6 under hypoxia using si-PKM2. The number of C4-2AT6 under chronic hypoxia exposed to siPKM2 significantly decreased compared to intact C4-2AT6 under chronic hypoxia. Furthermore, si-PKM2 improved resistance to mTOR inhibitor in C4-2AT6. When examined using clinical samples, high PKM2 expression was correlated with a high Gleason score and poor PSA free survival. These results suggested that up-regulation of PKM2 is one possibility of resistance to mTOR inhibitor in CRPC. And it is possible that PKM2 is a useful therapeutic target of CRPC.

KW - C4-2AT6

KW - CRPC

KW - Hypoxias

KW - PI3K-Akt-mTOR signaling pathways

KW - PKM2

UR - http://www.scopus.com/inward/record.url?scp=85048372828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048372828&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25498

DO - 10.18632/oncotarget.25498

M3 - Article

VL - 9

SP - 27698

EP - 27707

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -